Short Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Expands By 17.0%

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 12,350,000 shares, a growth of 17.0% from the March 31st total of 10,560,000 shares. Based on an average daily volume of 1,620,000 shares, the days-to-cover ratio is currently 7.6 days.

Insider Activity

In related news, Director Jonathan Finn bought 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was bought at an average cost of $1.77 per share, for a total transaction of $44,250.00. Following the acquisition, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $44,250. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Atossa Therapeutics

An institutional investor recently bought a new position in Atossa Therapeutics stock. PFG Investments LLC bought a new stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 23,650 shares of the company’s stock, valued at approximately $43,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Trading Up 0.7 %

NASDAQ ATOS traded up $0.01 on Friday, hitting $1.53. The company’s stock had a trading volume of 900,111 shares, compared to its average volume of 2,648,768. Atossa Therapeutics has a 52-week low of $0.59 and a 52-week high of $2.31. The company’s 50-day simple moving average is $1.44 and its 200 day simple moving average is $1.02.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.06) earnings per share for the quarter. On average, analysts forecast that Atossa Therapeutics will post -0.28 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Atossa Therapeutics in a report on Tuesday, April 16th. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a report on Friday, January 12th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.